Hepatitis B - telbivudine (TA154)
Fast, easy summary view of NICE guidance on 'hepatitis b chronic'
Telbivudine is not recommended for people with chronic hepatitis B. Healthcare professionals should not stop prescribing telbivudine for people who were already taking it when the guidance was issued.These patients should be able to carry on taking telbivudine until they and their healthcareprofessionals decide that it is the right time to stop treatment.
We will consult on our review plans for this guidance in February 2009.
This guidance has been incorporated into the following NICE Pathways, along with other related guidance and products.
Visit the NICE Pathway: hepatitis b chronic
This page was last updated: 24 June 2013
- Web format
- Quick reference guide (PDF)
- Full Guidance (PDF)
- TA154 Telbivudine ar gyfer hepatitis B cronig: deall canllawiau NICE (fformat MS Word)
Information for the public
Implementation tools and resources
See this guidance in practice
The summary of the key recommendations in the guidance written for patients, carers and those with little medical knowledge and may be used in local patient information leaflets.
Quick Reference Guide
The quick reference guide presents recommendations for health professionals
The published NICE clinical guidance, contains the recommendations for health professionals and NHS bodies.
The published full clinical guidance for specialists with background, evidence, recommendations and methods used.